@article{73c97a760ea14624b53b7b40b50dc2f5,
title = "Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale",
abstract = "Background: Approximately 86–89% of patients with BD have a comorbid anxiety disorder associated with poor quality of life and reduced likelihood of recovery from an acute mood episode. The purpose of this study is to assess the prevalence and impact of comorbid anxiety using the Bipolar Inventory of Symptoms Scale (BISS) in patients with BD who participated in a 6-month pragmatic trial. Methods: Participants (N = 482) in the Bipolar Clinical Health Outcomes Initiative in Comparative Effectiveness (CHOICE) study were adults with BD I or II. Anxiety diagnoses were assessed with the MINI. Global illness severity was assessed using the Clinical Global Impression-Bipolar Version. Mood symptoms and anxiety severity were assessed using the BISS. Results: 61% of the study sample met criteria for a current anxiety disorder. Patients with a higher BISS anxiety score at baseline had a higher overall BD illness severity, depressive severity, and manic episode severity (p < 0.001). A single cutoff value of BISS anxiety had great sensitivity, yet poor specificity for determining a comorbid anxiety diagnosis. There were no significant differences in outcomes for individuals treated for anxiety disorders with anxiolytics compared with those who were not treated with anxiolytics. Limitations: Sample size limitations prevented an analysis of whether the BISS cutoff score of 10 performed differently across varied anxiety disorders. Conclusions: Given its ability to identify patients with co-occurring anxiety, the BISS anxiety subscale shows clinical utility as a screening measure though its application as a clinical assessment measure may not be advisable.",
keywords = "Anxiety disorders, Bipolar disorder, Bipolar inventory of symptoms scale, Comparative effectiveness research, Mood disorders",
author = "Gustavo Kinrys and Bowden, {Charles L.} and Nierenberg, {Andrew A.} and Hearing, {Casey M.} and Gold, {Alexandra K.} and Rabideau, {Dustin J.} and Sylvia, {Louisa G.} and Keming Gao and Masoud Kamali and Bobo, {William V.} and Mauricio Tohen and Thilo Deckersbach and McElroy, {Susan L.} and Ketter, {Terence A.} and Shelton, {Richard C.} and Friedman, {Edward S.} and Calabrese, {Joseph R.} and McInnis, {Melvin G.} and James Kocsis and Thase, {Michael E.} and Vivek Singh and Reilly-Harrington, {Noreen A.}",
note = "Funding Information: Dr. Singh received research funding from Astra Zeneca and Novartis. He was on the Speaker Bureau for Merck and Sunovion. He consulted with Forum Pharmaceuticals. Funding Information: Dr. Bobo has received research support from NIMH, AHRQ, and the Mayo Foundation for Medical Education and Research. Funding Information: Dr. Kocsis has received research grants and contracts from AHRQ, NIMH, Pritzker Consortium, Qatar National Research Fund, and Rockefeller Treatment Development Fund. He holds an Elan Patent (No. 8,853,279), entitled “Method for Determining Sensitivity or Resistance to Compounds That Activate the Brain Serotonin System.” Funding Information: This study was supported in part by the Dauten Family Center for Bipolar Treatment Innovation Funding Information: Dr. Kinrys has received research support from Astra-Zeneca, Bristol-Myers Squibb Company, Cephalon, Elan Pharmaceuticals, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, Sanofi/Synthelabo, Sepracor Inc., Pfizer Inc, UCB Pharma, and Wyeth-Ayerst Laboratories, Agency for Healthcare Research and Quality (AHRQ) Grant R01 HS019371-01, and Takeda Pharmaceuticals. He has been an advisor or consultant for Astra-Zeneca, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, Janssen Pharmaceutica, Pfizer Inc, Sepracor Inc., UCB Pharma, and Wyeth-Ayerst Laboratories. Dr. Kinrys has been a speaker for Astra-Zeneca, Forest Pharmaceuticals Inc., GlaxoSmithkline, Sepracor Inc., and Wyeth-Ayerst Laboratories. Funding Information: Dr. McInnis has received grants for research support from NIMH, the Heinz C Prechter Research Fund, and the Michigan Institute for Clinical Health Research (MICHR). MM has received consulting income from the Qatar National Research Foundation, Janssen, and Merck Pharmaceuticals. Funding Information: Dr. Gao was on a speakers bureau of AstraZeneca, Sunovion, and Pfizer; an advisory board of Sunovion and Otsuka; and received grant supports from AstraZeneca, Brain and Behavior Research Foundation, and Cleveland Foundation Funding Information: Dr. Deckersbach's research has been funded by NIH, NIMH, NARSAD, TSA, IOCDF, Tufts University, DBDAT, Otsuka Pharmaceuticals, Cogito Inc., and Sunovion. He has received honoraria, consultation fees and/or royalties from the MGH Psychiatry Academy, BrainCells Inc., Clintara, LLC., Systems Research and Applications Corporation, Boston University, the Catalan Agency for Health Technology Assessment and Research, the National Association of Social Workers Massachusetts, the Massachusetts Medical Society, Tufts University, NIDA, NIMH, and Oxford University Press. He has also participated in research funded by DARPA, NIH, NIMH, NIA, AHRQ, PCORI, Janssen Pharmaceuticals, The Forest Research Institute, Shire Development Inc., Medtronic, Cyberonics, Northstar, Takeda, and Sunovion. Funding Information: Dr. Calabrese has received federal funding from the Department of Defense, Health Resources Services Administration and National Institute of Mental Health as well as grant support from: Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb Company; Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.); Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Intra-Cellular Therapies, Inc.; Pfizer, Inc; H. Lundbeck A/S; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited. Dr. Calabrese has served as a consultant/advisory board member/speaker for: Abbott Laboratories; Allergan; AstraZeneca; Bristol-Myers Squibb Company; Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.); Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; H. Lundbeck A/S; Merck & Co., Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc; Repligen Corporation; Servier; Sunovion Pharmaceuticals Inc.; Solvay Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited. Funding Information: This study was funded by the Agency for Healthcare Research & Quality ( AHRQ ): 1R01HS019371-01 Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",
year = "2019",
month = mar,
day = "1",
doi = "10.1016/j.jad.2018.12.039",
language = "English (US)",
volume = "246",
pages = "126--131",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
}